Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer drug venetoclax gets Long-Term safety check

NCT ID NCT03844048

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it is over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

165 people

The number who actually took part.

Started

Sep 2019

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug. * Male subject agrees to refrain from sperm donation. * Female subjects must not be pregnant or breastfeeding. Exclusion Criteria: \- None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphoblastic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia cancer neoplasm non-Hodgkin lymphoma plasma cell myeloma Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphoblastic leukemia Acute myeloid leukemia Cancer Chronic lymphocytic leukemia Multiple myeloma Non-Hodgkin's lymphoma

Contacts and locations

Locations

  • Aarhus Universitetshospital - Skejby /ID# 224214

    Aarhus, Central Jutland, 8200, Denmark

  • Ankara Univ Medical Faculty /ID# 225043

    Ankara, 06590, Turkey (Türkiye)

  • Aotearoa Clinical Trials /ID# 225596

    Papatoetoe, Auckland, 2025, New Zealand

  • Beaumont Hospital /ID# 225165

    Dublin, D09 XR63, Ireland

  • Blackpool Teaching Hospitals NHS Foundation Trust /ID# 225163

    Blackpool, FY3 8NR, United Kingdom

  • CHU Grenoble - Hopital Michallon /ID# 240497

    La Tronche, Isere, 38700, France

  • CHUQ- Hôpital de l'Enfant-Jesus /ID# 224616

    Québec, Quebec, G1J 1Z4, Canada

  • Centro de Investigacion Clínica Chapultepec SA de CV /ID# 227018

    Morelia, Michoacán, 58260, Mexico

  • China Medical University Hospital /ID# 224945

    Taichung, 40447, Taiwan

  • Clatterbridge Cancer Centre - Liverpool /ID# 218736

    Liverpool, L7 8YA, United Kingdom

  • Cliniques Universitaires UCL Saint-Luc /ID# 224327

    Brussels, Brussels Capital, 1200, Belgium

  • Dana-Farber Cancer Institute /ID# 215360

    Boston, Massachusetts, 02215, United States

  • Dartmouth-Hitchcock Medical Center /ID# 210555

    Lebanon, New Hampshire, 03756, United States

  • Derriford Hospital and the Royal Eye Infirmary /ID# 218731

    Plymouth, Devon, PL6 8DH, United Kingdom

  • Duplicate_Medizinische Universitaet Graz /ID# 223817

    Graz, Styria, 8010, Austria

  • Duplicate_National Hospital Organization Mito Medical Center /ID# 241986

    Higashi Ibaraki-gun, Ibaraki, 311-3193, Japan

  • Duplicate_Okayama Medical Center /ID# 241517

    Okayama, Okayama-ken, 701-1192, Japan

  • Duplicate_Pratia MCM Krakow /ID# 218561

    Krakow, Lesser Poland Voivodeship, 30-727, Poland

  • Duplicate_Skane University Hospital Lund /ID# 224747

    Lund, Skåne County, 221 41, Sweden

  • Federal State Budgetary Scientific Institution N.N. Blokhin /ID# 225194

    Moscow, Moscow, 115478, Russia

  • Fiona Stanley Hospital /ID# 239480

    Murdoch, Western Australia, 6150, Australia

  • General Hospital of Athens Laiko /ID# 224087

    Athens, Attica, 11527, Greece

  • General Hospital of Thessaloniki George Papanikolaou /ID# 224088

    Thessaloniki, 57010, Greece

  • HCL - Hopital Lyon Sud /ID# 213508

    Pierre-Bénite, Rhone, 69495, France

  • Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 227017

    Monterrey, Nuevo León, 64460, Mexico

  • Hospital Universitario Fundacion Jimenez Diaz /ID# 225476

    Madrid, 28040, Spain

  • IPO Lisboa FG, EPE /ID# 225072

    Lisbon, 1099-023, Portugal

  • Ingalls Memorial Hosp /ID# 210553

    Harvey, Illinois, 60426, United States

  • Instytut Hematologii i Transfuzjologii /ID# 225478

    Warsaw, Masovian Voivodeship, 02-776, Poland

  • Istanbul University Istanbul Medical Faculty /ID# 225045

    Istanbul, 34093, Turkey (Türkiye)

  • Kings College Hospital NHS Foundation Trust /ID# 218735

    London, Greater London, SE5 9RS, United Kingdom

  • Kobe City Medical Center General Hospital /ID# 241518

    Kobe, Hyōgo, 650-0047, Japan

  • Leicester Royal Infirmary /ID# 240468

    Leicester, England, LE1 5WW, United Kingdom

  • Liverpool Hospital /ID# 225591

    Liverpool, New South Wales, 2170, Australia

  • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council /ID# 240575

    Dnipro, 49102, Ukraine

  • National Cancer Center Hospital /ID# 241516

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Taiwan University Hospital /ID# 224946

    Taipei City, Taipei, 100, Taiwan

  • North Shore Hospital /ID# 225597

    Takapuna, Auckland, 0622, New Zealand

  • Perth Blood Institute Ltd /ID# 225592

    Nedlands, Western Australia, 6009, Australia

  • Peter MacCallum Cancer Ctr /ID# 210559

    Melbourne, Victoria, 3000, Australia

  • Queen Mary Hospital /ID# 224944

    Hong Kong, 999077, Hong Kong

  • Regional Oncological Dispensary /ID# 225195

    Penza, Penza Oblast, 440071, Russia

  • Rigshospitalet /ID# 224213

    Copenhagen Ø, Capital Region, 2100, Denmark

  • Royal Prince Alfred Hospital /ID# 239557

    Camperdown, New South Wales, 2050, Australia

  • SP ZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 225474

    Chorzów, Silesian Voivodeship, 41-500, Poland

  • Samsung Medical Center /ID# 240882

    Seoul, Seoul Teugbyeolsi, 06351, South Korea

  • St George Hospital /ID# 225589

    Kogarah, New South Wales, 2217, Australia

  • Swedish Medical Center - Seattle /ID# 213120

    Seattle, Washington, 98104, United States

  • The Royal Wolverhampton NHS Trust /ID# 225164

    Wolverhampton, WV10 0QP, United Kingdom

  • UCLA Santa Monica Hematology Oncology /ID# 210551

    Los Angeles, California, 90095, United States

  • University College London Hospital /ID# 240467

    London, Greater London, NW1 2BU, United Kingdom

  • University Hospital Southampton NHS Foundation Trust /ID# 225161

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • University of Arizona Cancer Center - Tucson /ID# 210548

    Tucson, Arizona, 85724, United States

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132

    Ann Arbor, Michigan, 48109, United States

  • Vehbi Koc vakfi Amerikan Hasta /ID# 225046

    Istanbul, 34365, Turkey (Türkiye)

  • Wellington Regional Hospital /ID# 225593

    Newtown, Wellington Region, 6021, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.